Option chain shows key data for Provectus's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Provectus.

Provectus (OTC:PVCT) Stock, Option Chain

Provectus

Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its HX molecule is named rose bengal sodium. The Company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.

Penny Stocks

Short Ideas

PVCT

On Monday, shares of Provectus Biopharm (OTC: PVCT) experienced volatile short activity. After the activity, the stock price went up +7.53% to $0.14.

The overall sentiment for PVCT has been Bullish.

Short Volatility Alert: Provectus Biopharm

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group’s Most Active List In December

Small Cap

Markets

AERG

ATLX

CLNV

CYDY

DTEGY

ETHE

GBTC

GTBIF

HEINY

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

NBLD

OTCM

REII

RHHBY

WMMVY

ZURVY

On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate had jumped 25 basis points, 50 basis points and then 75 points four times in a row in between each Federal Reserve meeting.  

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group&#39;s Most Active List In December

News

Press Releases

Provectus Will Report Data on PV-10 in Combo Therapy, T-Cell Mediated Immunity at AACR Meeting

PROVECTUS BIOPHARMS by Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals Inc

Provectus Biopharmaceuticals Announces Management Additions and Reiterates Commitment to Shareholder Value Creation

Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers

Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Provectus Biopharmaceuticals Announces Investor Webinar for 2024 Annual Meeting of Stockholders

Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference Call

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call

Provectus Biopharmaceuticals Launches VisiRose, Provectus's Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology

Provectus Biopharmaceuticals Announces Seed Financing for VisiRose, Provectus's Spinoff Company for Rose Bengal-Based Eye Drugs

Comments

Provectus

Provectus (PVCT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga